Because PD-1/PD-L1 monotherapy yields <10% responses in relapsed osteosarcoma, interrupting this circuit via TRK/RET inhibition or macrophage re-education may unlock checkpoint synergy. The gene discussed is NTRK1; the disease is osteosarcoma.